Agency Forms Undergoing Paperwork Reduction Act Review, 12494-12496 [2016-05235]
Download as PDF
<![CDATA[
12494
Federal Register / Vol. 81, No. 46 / Wednesday, March 9, 2016 / Notices
collection requirement concerning the
Make-or-Buy Program.
DATES: Submit comments on or before
May 9, 2016.
ADDRESSES: Submit comments
identified by Information Collection
9000–0078, Make-or-Buy Program, by
any of the following methods:
• Regulations.gov: https://
www.regulations.gov. Submit comments
via the Federal eRulemaking portal by
searching the OMB control number.
Select the link ‘‘Submit a Comment’’
that corresponds with ‘‘Information
Collection 9000–0078, Make-or-Buy
Program’’. Follow the instructions
provided at the ‘‘Submit a Comment’’
screen. Please include your name,
company name (if any), and
‘‘Information Collection 9000–0078,
Make-or-Buy Program’’ on your attached
document.
• Mail: General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW.,
Washington, DC 20405. ATTN: Ms.
Flowers/IC 9000–0078, Make-or-Buy
Program.
Instructions: Please submit comments
only and cite Information Collection
9000–0078, Make-or-Buy Program, in all
correspondence related to this
collection. Comments received generally
will be posted without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two to three days after
submission to verify posting (except
allow 30 days for posting of comments
submitted by mail).
FOR FURTHER INFORMATION CONTACT: Mr.
Edward Loeb, Procurement Analyst,
Office of Acquisition Policy, GSA, 202–
501–0650 or via email at edward.loeb@
gsa.gov.
SUPPLEMENTARY INFORMATION:
Lhorne on DSK5TPTVN1PROD with NOTICES
A. Purpose
Price, performance, and/or
implementation of socio-economic
policies may be affected by make-or-buy
decisions under certain Government
prime contracts. Accordingly, FAR
15.407–2, Make-or-Buy Programs:
(i) Sets forth circumstances under
which a Government contractor must
submit for approval by the contracting
officer a make-or-buy program, i.e., a
written plan identifying major items to
be produced or work efforts to be
performed in the prime contractor’s
facilities and those to be subcontracted;
(ii) Provides guidance to contracting
officers concerning the review and
VerDate Sep<11>2014
15:08 Mar 08, 2016
Jkt 238001
approval of the make-or-buy programs;
and
(iii) Prescribes the contract clause at
FAR 52.215–9, Changes or Additions to
Make-or-Buy Programs, which specifies
the circumstances under which the
contractor is required to submit for the
contracting officer’s advance approval a
notification and justification of any
proposed change in the approved makeor-buy program.
The information is used to assure the
lowest overall cost to the Government
for required supplies and services.
B. Annual Reporting Burden
Respondents: 150.
Responses Per Respondent: 3.
Total Responses: 450.
Hours per Response: 8.
Total Burden Hours: 3,600.
C. Public Comments
Public comments are particularly
invited on: Whether this collection of
information is necessary for the proper
performance of functions of the Federal
Acquisition Regulation (FAR), and
whether it will have practical utility;
whether our estimate of the public
burden of this collection of information
is accurate, and based on valid
assumptions and methodology; ways to
enhance the quality, utility, and clarity
of the information to be collected; and
ways in which we can minimize the
burden of the collection of information
on those who are to respond, through
the use of appropriate technological
collection techniques or other forms of
information technology.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW., Washington, DC
20405, telephone 202–501–4755. Please
cite OMB Control No. 9000–0078, Makeor-Buy Program, in all correspondence.
Dated: March 3, 2016.
Lorin S. Curit,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–16CM]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
[FR Doc. 2016–05204 Filed 3–8–16; 8:45 am]
Proposed Project
BILLING CODE 6820–EP–P
The Cooperative Re-engagement
Controlled Trial (CoRECT)—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\09MRN1.SGM
09MRN1
12495
Federal Register / Vol. 81, No. 46 / Wednesday, March 9, 2016 / Notices
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC), National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Division of
HIV/AIDS Prevention (DHAP) requests a
new three year OMB approval for
information collection for a new
research study entitled ‘‘The
Cooperative Re-engagement Controlled
Trial (CoRECT)’’. The purpose of the
study is to evaluate a combined health
department and clinic intervention to
improve engagement in HIV care.
Increasing the number of people living
with HIV who access HIV care and
achieve viral load suppression
addresses one of the priorities of the
National HIV/AIDS Strategy. The data
collection is authorized under the
Section 301 of the Public Health Service
Act (42 U.S.C. 241).
The CoRECT Study data collection is
comprised of six core components: 1.
Electronic clinic data abstraction
(Electronic Medical Record (EMR)
abstraction will be conducted by project
clinic staff at each project clinic to
develop the clinic-based ‘‘Out of Care’’
list;) 2. electronic surveillance data
abstraction (Electronic surveillance data
abstraction will be conducted by project
health department staff at each health
department to develop the health
department based ‘‘Out of Care’’ list); 3.
a ‘‘Barriers to Care’’ survey (These
surveys will provide information
regarding barriers to accessing
healthcare (e.g., transportation, financial
assistance, housing, substance abuse
services, etc.)); 4. a ‘‘Standard of Care’’
survey (Investigators will administer
this survey to clinic managers, at
baseline and every six months during
the study period to assess how the
delivery of health services has evolved
over time); 5. a Participant Eligibility
Disposition form (a listing of potential
out-of-care patients will be reviewed to
determine those who appear to be outof-care, as determined by study
eligibility, versus those who meet
criteria for exclusion); and 6. a Case
Conference form (project health
department staff will determine if
potentially eligible patients met criteria
for inclusion in the study and if so
randomization will occur). Prospective
data collection will provide information
about participant’s baseline
characteristics including sex, race/
ethnicity, HIV exposure risk category,
CD4 and viral load test results, date of
first clinic visit, and insurance status.
HIV antiretroviral therapy (ART) can
durably suppress the plasma HIV viral
load, which improves individual
survival and dramatically reduces
further HIV transmission. Increasing the
number of people living with HIV who
access HIV care and achieve viral load
suppression is a priority of the National
HIV/AIDS Strategy. Within the
continuum of HIV care in the United
States, improvements in linkage to and
retention in effective care provide the
greatest opportunity to improve rates of
HIV viral suppression. It is estimated
that of the 1.2 million persons living
with HIV in 2011, only 40% were
engaged in HIV medical care and only
30% achieved viral suppression.
HIV clinical trials with enhanced case
management have demonstrated that
interventions provided by the health
department can improve linkage to HIV
care and interventions provided by the
clinic can improve retention in HIV
care. Although linkage to care has
improved in many health department
jurisdictions, being linked to care is not
enough. There is a need to ensure that:
(i) People diagnosed with HIV and
linked to care are engaging medical care
(i.e., attending their enrollment
appointment and returning for followup medical appointments); and (ii)
people who have disengaged from HIV
care (i.e., have missed medical
appointments and have not been seen in
clinic for more than 6 months) are able
to efficiently re-engage in care. There
have been no randomized controlled
studies using a Data-to-Care approach to
identify and re-engage out of care
persons. Controlled studies such as the
CoRECT study are critical to determine
the effectiveness of HIV prevention
interventions.
The CoRECT study is a randomized
controlled trial that seeks to establish a
data-sharing partnership between health
departments and HIV care clinical
providers to identify HIV-infected
persons who are out of care and
evaluate an intervention that aims to
have randomized participants: (a) Link
to an HIV clinic; (b) remain in HIV
medical care; (c) achieve HIV viral load
suppression within 12 months; and (d)
achieve durable HIV viral load
suppression over 18 months.
The study is funded by CDC through
cooperative agreements with the
Connecticut State Department of Public
Health (in collaboration with Yale
University School of Medicine), the
Massachusetts State Department of
Public Health, and the Philadelphia
Department of Public Health. The total
burden hours are 1,731.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Form name
CoRECT Study Coordinator ...........................
Lhorne on DSK5TPTVN1PROD with NOTICES
Type of respondent
Electronic transmittal of surveillance variables.
Electronic transmittal of clinical variables ......
Barriers to Care Survey .................................
Standard of Care Survey ...............................
Case Conference Session .............................
Case Conference Session .............................
3
4
1
46
1,200
46
46
3
4
1
2
12
12
1
30/60
45/60
1
1
Participant Eligibility Disposition form ............
3
12
1
Cost analysis form—baseline ........................
Start-up cost analysis form—Health department.
Start-up Cost Analysis form—Clinic ...............
Annual Costs Analysis form-Health department.
Annual Costs Analysis form—Clinic ..............
46
3
1
1
1
1
46
3
1
2
1
1.5
46
2
1.5
Clinic Data Manager .......................................
CoRECT Study Participants ...........................
Clinical Nurse Coordinator ..............................
Clinic Data Manager .......................................
CoRECT study Coordinator (health department).
CoRECT Study Coordinator (health department).
Clinic data manager ........................................
CoRECT Study Coordinator ...........................
Clinic Data Manager .......................................
CoRECT Study Coordinator ...........................
Clinic Data Manager .......................................
VerDate Sep<11>2014
15:08 Mar 08, 2016
Jkt 238001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\09MRN1.SGM
09MRN1
12496
Federal Register / Vol. 81, No. 46 / Wednesday, March 9, 2016 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–05235 Filed 3–8–16; 8:45 am]
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
Centers for Disease Control and
Prevention
[FR Doc. 2016–05266 Filed 3–8–16; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
Lhorne on DSK5TPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) DD 16–001, Centers for Autism
and Developmental Disabilities
Research and Epidemiology (CADDRE):
Study to Explore Early Development
(SEED) 3.
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, April 7, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘FOA DD16–001, Centers for Autism
and Developmental Disabilities
Research and Epidemiology (CADDRE):
Study to Explore Early Development
(SEED) 3’’.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
VerDate Sep<11>2014
15:08 Mar 08, 2016
Jkt 238001
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA), DP 16–002, Michigan Lupus
Epidemiology and Surveillance (MILES)
Program Longitudinal Cohort Study.
Time and Date: 11:00 a.m.–6:00 p.m.,
EDT, April 5, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘FOA DP16–002, Michigan Lupus
Epidemiology and Surveillance (MILES)
Program Longitudinal Cohort Study’’.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–05267 Filed 3–8–16; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Board of Scientific Counselors, Office
of Infectious Diseases (BSC, OID)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 2:00–4:00 p.m., EDT,
March 28, 2016.
Place: Teleconference.
Status: The meeting is open to the
public; the toll free dial in number is 1–
877–951–7311 with a pass code of
7972741.
Purpose: The BSC, OID, provides
advice and guidance to the Secretary,
Department of Health and Human
Services; the Director, CDC; the
Director, OID; and the Directors of the
National Center for Immunization and
Respiratory Diseases, the National
Center for Emerging and Zoonotic
Infectious Diseases, and the National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention, CDC, in the
following areas: Strategies, goals, and
priorities for programs; research within
the national centers; and overall
strategic direction and focus of OID and
the national centers.
Matters for Discussion: Topics to be
discussed during the teleconference
include administrative/budget issues,
current emerging infectious disease
outbreak responses, and reports from
recent program meetings.
The agenda and any supplemental
material will be available at
www.cdc.gov/oid/BSC/
meetingschedule.html after March 20.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Robin Moseley, M.A.T., Designated
Federal Officer, OID, CDC, 1600 Clifton
Road NE., Mailstop D10, Atlanta,
Georgia 30333, Telephone: (404) 639–
4461.
The Director, Management Analysis
and Services Office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 81, Number 46 (Wednesday, March 9, 2016)]
[Notices]
[Pages 12494-12496]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-05235]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-16CM]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
The Cooperative Re-engagement Controlled Trial (CoRECT)--New--
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control and Prevention (CDC).
[[Page 12495]]
Background and Brief Description
The Centers for Disease Control and Prevention (CDC), National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Division of HIV/AIDS Prevention (DHAP) requests a new three year OMB
approval for information collection for a new research study entitled
``The Cooperative Re-engagement Controlled Trial (CoRECT)''. The
purpose of the study is to evaluate a combined health department and
clinic intervention to improve engagement in HIV care. Increasing the
number of people living with HIV who access HIV care and achieve viral
load suppression addresses one of the priorities of the National HIV/
AIDS Strategy. The data collection is authorized under the Section 301
of the Public Health Service Act (42 U.S.C. 241).
The CoRECT Study data collection is comprised of six core
components: 1. Electronic clinic data abstraction (Electronic Medical
Record (EMR) abstraction will be conducted by project clinic staff at
each project clinic to develop the clinic-based ``Out of Care'' list;)
2. electronic surveillance data abstraction (Electronic surveillance
data abstraction will be conducted by project health department staff
at each health department to develop the health department based ``Out
of Care'' list); 3. a ``Barriers to Care'' survey (These surveys will
provide information regarding barriers to accessing healthcare (e.g.,
transportation, financial assistance, housing, substance abuse
services, etc.)); 4. a ``Standard of Care'' survey (Investigators will
administer this survey to clinic managers, at baseline and every six
months during the study period to assess how the delivery of health
services has evolved over time); 5. a Participant Eligibility
Disposition form (a listing of potential out-of-care patients will be
reviewed to determine those who appear to be out-of-care, as determined
by study eligibility, versus those who meet criteria for exclusion);
and 6. a Case Conference form (project health department staff will
determine if potentially eligible patients met criteria for inclusion
in the study and if so randomization will occur). Prospective data
collection will provide information about participant's baseline
characteristics including sex, race/ethnicity, HIV exposure risk
category, CD4 and viral load test results, date of first clinic visit,
and insurance status.
HIV antiretroviral therapy (ART) can durably suppress the plasma
HIV viral load, which improves individual survival and dramatically
reduces further HIV transmission. Increasing the number of people
living with HIV who access HIV care and achieve viral load suppression
is a priority of the National HIV/AIDS Strategy. Within the continuum
of HIV care in the United States, improvements in linkage to and
retention in effective care provide the greatest opportunity to improve
rates of HIV viral suppression. It is estimated that of the 1.2 million
persons living with HIV in 2011, only 40% were engaged in HIV medical
care and only 30% achieved viral suppression.
HIV clinical trials with enhanced case management have demonstrated
that interventions provided by the health department can improve
linkage to HIV care and interventions provided by the clinic can
improve retention in HIV care. Although linkage to care has improved in
many health department jurisdictions, being linked to care is not
enough. There is a need to ensure that: (i) People diagnosed with HIV
and linked to care are engaging medical care (i.e., attending their
enrollment appointment and returning for follow-up medical
appointments); and (ii) people who have disengaged from HIV care (i.e.,
have missed medical appointments and have not been seen in clinic for
more than 6 months) are able to efficiently re-engage in care. There
have been no randomized controlled studies using a Data-to-Care
approach to identify and re-engage out of care persons. Controlled
studies such as the CoRECT study are critical to determine the
effectiveness of HIV prevention interventions.
The CoRECT study is a randomized controlled trial that seeks to
establish a data-sharing partnership between health departments and HIV
care clinical providers to identify HIV-infected persons who are out of
care and evaluate an intervention that aims to have randomized
participants: (a) Link to an HIV clinic; (b) remain in HIV medical
care; (c) achieve HIV viral load suppression within 12 months; and (d)
achieve durable HIV viral load suppression over 18 months.
The study is funded by CDC through cooperative agreements with the
Connecticut State Department of Public Health (in collaboration with
Yale University School of Medicine), the Massachusetts State Department
of Public Health, and the Philadelphia Department of Public Health. The
total burden hours are 1,731.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
CoRECT Study Coordinator.............. Electronic transmittal 3 4 1
of surveillance
variables.
Clinic Data Manager................... Electronic transmittal 46 4 1
of clinical variables.
CoRECT Study Participants............. Barriers to Care Survey. 1,200 1 30/60
Clinical Nurse Coordinator............ Standard of Care Survey. 46 2 45/60
Clinic Data Manager................... Case Conference Session. 46 12 1
CoRECT study Coordinator (health Case Conference Session. 3 12 1
department).
CoRECT Study Coordinator (health Participant Eligibility 3 12 1
department). Disposition form.
Clinic data manager................... Cost analysis form-- 46 1 1
baseline.
CoRECT Study Coordinator.............. Start-up cost analysis 3 1 1
form--Health department.
Clinic Data Manager................... Start-up Cost Analysis 46 1 1
form--Clinic.
CoRECT Study Coordinator.............. Annual Costs Analysis 3 2 1.5
form-Health department.
Clinic Data Manager................... Annual Costs Analysis 46 2 1.5
form--Clinic.
----------------------------------------------------------------------------------------------------------------
[[Page 12496]]
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2016-05235 Filed 3-8-16; 8:45 am]
BILLING CODE 4163-18-P
